The Tufts study.

The Tufts study, in collaboration with researchers at the Thomas Jefferson University in Philadelphia, published this month in the journal Infection and Immunity , and was supported by National Institutes of Allergy and Infectious Diseases and the New England Regional Center financed for Excellence for biodefense and Emerging Infectious Diseases. – We have proven this approach to protect against Botulinum intoxication in mice and we hope that this will lead to a rapid development and deployment of many new anti-toxin therapies – for botulism and beyond, said Charles B. Shoemaker, Professor of Biomedicine at the Tufts University Cummings School of Veterinary Medicine and the study the author. – The new findings on a 2002 breakthrough at the University of California in San Francisco product shelf-life combined three monoclonal antibodies against botulinum toxin bound to expand to different parts of the toxin molecule.

Botulinum toxin , which causes botulism, is acutely toxic substance toxic substance and is one of the most dangerous bioterrorism threats considered. Studies have shown that one gram of the toxin , which is produced by a bacterium that lives in the soil, could kill a million people. Although currently available antitoxins can be mass produced and delivered in the event of an outbreak, they are expensive to develop, deliver and home – and have a short shelf life. (more…)

Page 2 of 212